Cardiac consequences of anti-inflammatory drugs in experimental models

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 12, Issue 1, 2013, Pages 24-35

  Merlet, Nolwenn ^a   Busseuil, David ^a   Rhéaume, Éric ^a   Tardif, Jean Claude ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Biologics; Cardiac hypertrophy; Cardiotoxic drugs; Experimental models; Glucocorticoids; Heart failure; Ischemia reperfusion; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIINFLAMMATORY AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CELECOXIB; CREATINE KINASE; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DICLOFENAC; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; HEAT SHOCK PROTEIN 72; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IBUPROFEN; INDOMETACIN; INFLIXIMAB; KETOPROFEN; METHYLPREDNISOLONE; NAPROXEN; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; ROFECOXIB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

APOPTOSIS; AUTOIMMUNE DISEASE; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; GENETIC TRANSCRIPTION; HEART DEVELOPMENT; HEART DISEASE; HEART FIBRILLATION; HEART FUNCTION; HEART INFARCTION; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOPLASIA; INFLAMMATION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; REVIEW; SIDE EFFECT; TACHYCARDIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; HEART; HUMANS; MICE; MUSCLE CELLS; RATS;

EID: 84875853437     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/1871523011312010005     Document Type: Review

References (140)

1. Rona, G. Catecholamine cardiotoxicity. J. Mol. Cell Cardiol., 1985, 17 (4), 291-306.
2. Nichtova, Z.; Novotova, M.; Kralova, E.; Stankovicova, T. Morphological and functional characteristics of models of experimental myocardial injury induced by isoproterenol. Gen. Physiol. Biophys., 2012, 31 (2), 141-151.
3. Wasserstrom, J.A.; Aistrup, G.L. Digitalis: New actions for an old drug. Am. J. Physiol. Hear. t Circ. Physiol., 2005, 289 (5), H1781-1793.
4. Chaggar, P.S.; Shaw, S.M.; Williams, S.G. Review article: Thiazolidinediones and heart failure. Diab. Vasc. Dis. Res., 2009, 6 (3), 146-152.
5. Octavia, Y.; Tocchetti, C.G.; Gabrielson, K.L.; Janssens, S.; Crijns, H.J.; Moens, A.L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell Cardiol., 2012, 52 (6), 1213-1225.
6. Elangbam, C.S. Drug-induced valvulopathy: an update. Toxicol. Pathol., 2010, 38 (6), 837-848.
7. De Bosscher, K.; Haegeman, G., Minireview: Latest perspectives on antiinflammatory actions of glucocorticoids. Mol. Endocrinol., 2009, 23 (3), 281-291.
8. Boldizsar, F.; Talaber, G.; Szabo, M.; Bartis, D.; Palinkas, L.; Nemeth, P.; Berki, T. Emerging pathways of non-genomic glucocorticoid (GC) signalling in T cells. Immunobiology,2010, 215(7), 521-526.
9. th edi ed.; Hamilton (ON): BC Decker: 2000; Chap. 54.
10. Rao, M.K.; Xu, A.; Narayanan, N. Glucocorticoid modulation of protein phosphorylation and sarcoplasmic reticulum function in rat myocardium. Am. J. Physiol. Heart Circ. Physiol., 2001, 281 (1), H325-333.
11. Bers, D.M. Cardiac excitation-contraction coupling. Nature, 2002, 415 (6868), 198-205.
12. Levitan, E.S.; Hershman, K.M.; Sherman, T.G.; Takimoto, K. Dexamethasone and stress upregulate Kv1.5 K+ channel gene expression in rat ventricular myocytes. Neuropharmacology, 1996, 35 (7), 1001-1006.
13. Narayanan, N.; Yang, C.; Xu, A. Dexamethasone treatment improves sarcoplasmic reticulum function and contractile performance in aged myocardium. Mol. Cell Biochem., 2004, 266 (1-2), 31-36.
14. Mizuno, M.; Takeba, Y.; Matsumoto, N.; Tsuzuki, Y.; Asoh, K.; Takagi, M.; Kobayashi, S.; Yamamoto, H. Antenatal glucocorticoid therapy accelerates ATP production with creatine kinase increase in the growth-enhanced fetal rat heart. Circ. J., 2010, 74 (1), 171-180.
15. Tsuzuki, Y.; Takeba, Y.; Kumai, T.; Matsumoto, N.; Mizuno, M.; Murano, K.; Asoh, K.; Takagi, M.; Yamamoto, H.; Kobayashi, S. Antenatal glucocorticoid therapy increase cardiac alpha-enolase levels in fetus and neonate rats. Life Sci., 2009, 85 (17-18), 609-616.
16. Guarino, N.; Shima, H.; Puri, P. Cardiac gene expression and synthesis of atrial natriuretic peptide in the nitrofen model of congenital diaphragmatic hernia in rats: Effect of prenatal dexamethazone treatment. J. Pediatr. Surg., 2001, 36(10), 1497-1501.
17. Guarino, N.; Shima, H.; Puri, P. Structural immaturity of the heart in congenital diaphragmatic hernia in rats. J. Pediatr. Surg., 2001, 36(5), 770-773.
18. Migliazza, L.; Xia, H.M.; Arnaiz, A.; Alvarez, J.I.; Alfonso, L.F.; Diez-Pardo, J.A.; Valls i Soler, A.; Tovar, J.A. Prenatal dexamethasone rescues heart hypoplasia in fetal rats with congenital diaphragmatic hernia. J. Pediatr. Surg., 2000, 35 (12), 1757-1761.
19. Guarino, N.; Puri, P. Antenatal dexamethasone enhances endothelin-1 synthesis and gene expression in the heart in congenital diaphragmatic hernia in rats. J. Pediatr. Surg., 2002, 37(11), 1563-1567.
20. Xu, B.; Strom, J.; Chen, Q.M. Dexamethasone induces transcriptional activation of Bcl-xL gene and inhibits cardiac injury by myocardial ischemia. Eur. J. Pharmacol., 2011, 668(1-2), 194-200.
21. Xia, Q.G.; Na, T.; Guo, Y. M.; Bi, Y.T.; Zhang, H.Y.; Dai, D.Z. Improvement of chronic heart failure by dexamethasone is not associated with downregulation of leptin in rats. Acta Pharmacol. Sin., 2007, 28(2), 202-210.
22. Van Kerckhoven, R.; van Veghel, R.; Saxena, P.R.; Schoemaker, R.G. Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts. Cardiovasc. Res., 2004, 61 (3), 620-629.
23. Zheng, W.; Brown, M.D.; Brock, T.A.; Bjercke, R.J.; Tomanek, R.J. Bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor. Circ. Res., 1999, 85(2), 192-198.
24. Valen, G.; Kawakami, T.; Tahepold, P.; Starkopf, J.; Kairane, C.; Dumitrescu, A.; Lowbeer, C.; Zilmer, M.; Vaage, J. Pretreatment with methylprednisolone protects the isolated rat heart against ischaemic and oxidative damage. Free Radic. Res., 2000, 33(1), 31-43.
25. Hutter, M.M.; Sievers, R.E.; Barbosa, V.; Wolfe, C.L. Heat-shock protein induction in rat hearts. A direct correlation between the amount of heat-shock protein induced and the degree of myocardial protection. Circulation, 1994, 89 (1), 355-360.
26. Suzuki, K.; Sawa, Y.; Kagisaki, K.; Taketani, S.; Ichikawa, H.; Kaneda, Y.; Matsuda, H. Reduction in myocardial apoptosis associated with overexpression of heat shock protein 70. Basic Res. Cardiol., 2000, 95(5), 397-403.
27. Quindry, J.C.; Hamilton, K.L.; French, J.P.; Lee, Y.; Murlasits, Z.; Tumer, N.; Powers, S.K. Exercise-induced HSP-72 elevation and cardioprotection against infarct and apoptosis. J. Appl. Physiol., 2007, 103(3), 1056-1062.
28. Tokudome, S.; Sano, M.; Shinmura, K.; Matsuhashi, T.; Morizane, S.; Moriyama, H.; Tamaki, K.; Hayashida, K.; Nakanishi, H.; Yoshikawa, N.; Shimizu, N.; Endo, J.; Katayama, T.; Murata, M.; Yuasa, S.; Kaneda, R.; Tomita, K.; Eguchi, N.; Urade, Y.; Asano, K.; Utsunomiya, Y.; Suzuki, T.; Taguchi, R.; Tanaka, H.; Fukuda, K. Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis. J. Clin. Invest., 2009, 119(6), 1477-1488.
29. Varga, E.; Nagy, N.; Lazar, J.; Czifra, G.; Bak, I.; Biro, T.; Tosaki, A. Inhibition of ischemia/reperfusion-induced damage by dexamethasone in isolated working rat hearts: The role of cytochrome c release. Life Sci., 2004, 75(20), 2411-2423.
30. Hafezi-Moghadam, A.; Simoncini, T.; Yang, Z.; Limbourg, F.P.; Plumier, J.C.; Rebsamen, M.C.; Hsieh, C.M.; Chui, D.S.; Thomas, K.L.; Prorock, A.J.; Laubach, V.E.; Moskowitz, M.A.; French, B.A.; Ley, K.; Liao, J.K. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med., 2002, 8(5), 473-479.
31. Kaljusto, M.L.; Stenslokken, K.O.; Mori, T.; Panchenko, A.; Frantzen, M.L.; Valen, G.; Vaage, J. Preconditioning effects of steroids and hyperoxia on cardiac ischemia-reperfusion injury and vascular reactivity. Eur. J. Cardiothorac. Surg., 2008, 33(3), 355-363.
32. Pearl, J.M.; Nelson, D.P.; Schwartz, S.M.; Wagner, C.J.; Bauer, S.M.; Setser, E.A.; Duffy, J.Y. Glucocorticoids reduce ischemiareperfusion-induced myocardial apoptosis in immature hearts. Ann. Thorac. Surg., 2002, 74(3), 830-836; discussion 836-7.
33. Duffy, J.Y.; Nelson, D.P.; Schwartz, S.M.; Wagner, C.J.; Bauer, S.M.; Lyons, J.M.; McNamara, J.L.; Pearl, J.M. Glucocorticoids reduce cardiac dysfunction after cardiopulmonary bypass and circulatory arrest in neonatal piglets. Pediatr. Crit. Care Med., 2004, 5(1), 28-34.
34. Schwartz, S.M.; Duffy, J.Y.; Pearl, J.M.; Goins, S.; Wagner, C.J.; Nelson, D.P. Glucocorticoids preserve calpastatin and troponin I during cardiopulmonary bypass in immature pigs. Pediatr. Res., 2003, 54(1), 91-97.
35. Pearl, J.M.; Plank, D.M.; McLean, K.M.; Wagner, C.J.; Duffy, J.Y. Glucocorticoids improve calcium cycling in cardiac myocytes after cardiopulmonary bypass. J. Surg. Res., 2011, 167(2), 279-286.
36. Farokhpour, M.; Karbalaie, K.; Tanhaei, S.; Nematollahi, M.; Etebari, M.; Sadeghi, H.M.; Nasr-Esfahani, M.H.; Baharvand, H. Embryonic stem cell-derived cardiomyocytes as a model system to study cardioprotective effects of dexamethasone in doxorubicin cardiotoxicity. Toxicol. in vitro 2009, 23(7), 1422-1428.
37. Chen, Q.M.; Alexander, D.; Sun, H.; Xie, L.; Lin, Y.; Terrand, J.; Morrissy, S.; Purdom, S. Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: Induction of antiapoptosis, antioxidant, and detoxification genes. Mol. PHARMACOL., 2005, 67(6), 1861-1873.
38. Bruynzeel, A.M.; Abou El Hassan, M.A.; Schalkwijk, C.; Berkhof, J.; Bast, A.; Niessen, H.W.; van der Vijgh, W.J. Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. Brit. J. Cancer, 2007, 96(6), 937-943.
39. Reeve, J.L.; Szegezdi, E.; Logue, S.E.; Chonghaile, T.N.; O'Brien, T.; Ritter, T.; Samali, A. Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL. J. Cell Mol. Med., 2007, 11(3), 509-520.
40. Hoshiai, M.; Hattan, N.; Hirota, Y.; Hoshiai, K.; Ishida, H.; Nakazawa, H. Impaired sarcoplasmic reticulum function in lipopolysaccharide-induced myocardial dysfunction demonstrated in whole heart. Shock, 1999, 11(5), 362-366.
41. Kewalramani, G.; Puthanveetil, P.; Wang, F.; Kim, M.S.; Deppe, S.; Abrahani, A.; Luciani, D. S.; Johnson, J.D.; Rodrigues, B. AMP-activated protein kinase confers protection against TNF-{alpha}-induced cardiac cell death. Cardiovasc. Res., 2009, 84(1), 42-53.
42. Sainte-Marie, Y.; Nguyen Dinh Cat, A.; Perrier, R.; Mangin, L.; Soukaseum, C.; Peuchmaur, M.; Tronche, F.; Farman, N.; Escoubet, B.; Benitah, J. P.; Jaisser, F. Conditional glucocorticoid receptor expression in the heart induces atrio-ventricular block. FASEB J., 2007, 21(12), 3133-3141.
43. Xue, Q.; Dasgupta, C.; Chen, M.; Zhang, L. Foetal hypoxia increases cardiac AT(2)R expression and subsequent vulnerability to adult ischaemic injury. Cardiovasc. Res., 2011, 89(2), 300-308.
44. Ludwig, M.; Steinhoff, G.; Li, J. The regenerative potential of angiotensin AT2 receptor in cardiac repair. Can. J. Physiol. Pharmacol., 2012, 90(3), 287-293.
45. Langdown, M.L.; Holness, M.J.; Sugden, M.C. Effects of prenatal glucocorticoid exposure on cardiac calreticulin and calsequestrin protein expression during early development and in adulthood. Biochem. J., 2003, 371(Pt 1), 61-69.
46. Guo, L.; Nakamura, K.; Lynch, J.; Opas, M.; Olson, E.N.; Agellon, L. B.; Michalak, M. Cardiac-specific expression of calcineurin reverses embryonic lethality in calreticulin-deficient mouse. J. Biol. Chem., 2002, 277(52), 50776-50779.
47. Mesaeli, N.; Nakamura, K.; Zvaritch, E.; Dickie, P.; Dziak, E.; Krause, K. H.; Opas, M.; MacLennan, D. H.; Michalak, M. Calreticulin is essential for cardiac development. J. Cell Biol., 1999, 144(5), 857-868.
48. Jones, L.R.; Suzuki, Y.J.; Wang, W.; Kobayashi, Y.M.; Ramesh, V.; Franzini-Armstrong, C.; Cleemann, L.; Morad, M. Regulation of Ca2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin. J. Clin. Invest., 1998, 101(7), 1385-1393.
49. Barak, Y.; Nelson, M. C.; Ong, E. S.; Jones, Y. Z.; Ruiz-Lozano, P.; Chien, K.R.; Koder, A.; Evans, R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell, 1999, 4(4), 585-595.
50. Langdown, M.L.; Sugden, M.C. Enhanced placental GLUT1 and GLUT3 expression in dexamethasone-induced fetal growth retardation. Mol. Cell Endocrinol., 2001, 185(1-2), 109-117.
51. Hillegass, J.M.; Villano, C.M.; Cooper, K.R.; White, L.A. Matrix metalloproteinase-13 is required for zebra fish (Danio rerio) development and is a target for glucocorticoids. Toxicol. Sci., 2007, 100(1), 168-179.
52. Dodic, M.; Peers, A.; Coghlan, J.P.; May, C.N.; Lumbers, E.; Yu, Z.; Wintour, E.M. Altered cardiovascular haemodynamics and baroreceptor-heart rate reflex in adult sheep after prenatal exposure to dexamethasone. Clin. Sci (Lond), 1999, 97(1), 103-109.
53. Dodic, M.; Samuel, C.; Moritz, K.; Wintour, E.M.; Morgan, J.; Grigg, L.; Wong, J. Impaired cardiac functional reserve and left ventricular hypertrophy in adult sheep after prenatal dexamethasone exposure. Circ. Res., 2001, 89(7), 623-629.
54. Bian, X.; Seidler, F. J.; Slotkin, T. A. Fetal dexamethasone exposure interferes with establishment of cardiac noradrenergic innervation and sympathetic activity. Teratology, 1993, 47(2), 109-117.
55. Bian, X.P.; Seidler, F.J.; Slotkin, T.A. Promotional role for glucocorticoids in the development of intracellular signalling: enhanced cardiac and renal adenylate cyclase reactivity to betaadrenergic and non-adrenergic stimuli after low-dose fetal dexamethasone exposure. J. Dev. Physiol., 1992, 17(6), 289-297.
56. Langdown, M.L.; Smith, N.D.; Sugden, M. C.; Holness, M. J. Excessive glucocorticoid exposure during late intrauterine development modulates the expression of cardiac uncoupling proteins in adult hypertensive male offspring. Pflugers Arch., 2001, 442 (2), 248-255.
57. Kamphuis, P.J.; de Vries, W.B.; Bakker, J.M.; Kavelaars, A.; van Dijk, J.E.; Schipper, M.E.; van Oosterhout, M.F.; Croiset, G.; Heijnen, C.J.; van Bel, F.; Wiegant, V.M. Reduced life expectancy in rats after neonatal dexamethasone treatment. Pediatr Res., 2007, 61(1), 72-76.
58. La Mear, N.S.; MacGilvray, S.S.; Myers, T.F. Dexamethasoneinduced myocardial hypertrophy in neonatal rats. Biol. Neonate., 1997, 72(3), 175-180.
59. de Vries, W.B.; Bal, M.P.; Homoet-van der Kraak, P.; Kamphuis, P.J.; van der Leij, F.R.; Baan, J.; Steendijk, P.; de Weger, R.A.; van Bel, F.; van Oosterhout, M.F. Suppression of physiological cardiomyocyte proliferation in the rat pup after neonatal glucocorticosteroid treatment. Basic Res. Cardiol., 2006, 101(1), 36-42.
60. de Vries, W.B.; van der Leij, F.R.; Bakker, J.M.; Kamphuis, P.J.; van Oosterhout, M. F.; Schipper, M. E.; Smid, G. B.; Bartelds, B.; van Bel, F. Alterations in adult rat heart after neonatal dexamethasone therapy. Pediatr. Res., 2002, 52(6), 900-906.
61. Bal, M.P.; de Vries, W.B.; van der Leij, F.R.; van Oosterhout, M.F.; Berger, R.M.; Baan, J.; van der Wall, E.E.; van Bel, F.; Steendijk, P. Neonatal glucocorticosteroid treatment causes systolic dysfunction and compensatory dilation in early life: studies in 4-week-old prepubertal rats. Pediatr. Res., 2005, 58(1), 46-52.
62. Bal, M.P.; de Vries, W.B.; Steendijk, P.; Homoet-van der Kraak, P.; van der Leij, F.R.; Baan, J.; van Oosterhout, M.F.; van Bel, F. Histopathological changes of the heart after neonatal dexamethasone treatment: studies in 4-, 8-, and 50-week-old rats. Pediatr. Res., 2009, 66(1), 74-79.
63. Bal, M.P.; de Vries, W.B.; van Oosterhout, M.F.; Baan, J.; van der Wall, E.E.; van Bel, F.; Steendijk, P. Long-term cardiovascular effects of neonatal dexamethasone treatment: hemodynamic follow-up by left ventricular pressure-volume loops in rats. J. Appl. Physiol., 2008, 104(2), 446-450.
64. Whitehurst, R.M., Jr.; Zhang, M.; Bhattacharjee, A.; Li, M. Dexamethasone-induced hypertrophy in rat neonatal cardiac myocytes involves an elevated L-type Ca(2+)current. J. Mol. Cell. Cardiol., 1999, 31(8), 1551-1558.
65. Seidler, F.J.; Slotkin, T.A. Developmental neurotoxicity targeting hepatic and cardiac sympathetic innervation: effects of organophosphates are distinct from those of glucocorticoids. Brain Res. Bull., 2011, 85 (3-4), 225-230.
66. Roy, S.G.; De, P.; Mukherjee, D.; Chander, V.; Konar, A.; Bandyopadhyay, D.; Bandyopadhyay, A. Excess of glucocorticoid induces cardiac dysfunction via activating angiotensin II pathway. Cell Physiol. Biochem., 2009, 24(1-2), 1-10.
67. De, P.; Roy, S. G.; Kar, D.; Bandyopadhyay, A. Excess of glucocorticoid induces myocardial remodeling and alteration of calcium signaling in cardiomyocytes. J. Endocrinol., 2011, 209(1), 105-114.
68. Ghose Roy, S.; Mishra, S.; Ghosh, G.; Bandyopadhyay, A. Thyroid hormone induces myocardial matrix degradation by activating matrix metalloproteinase-1. Matrix Biol., 2007, 26(4), 269-279.
69. Bauer, R.; Macgowan, G. A.; Blain, A.; Bushby, K.; Straub, V. Steroid treatment causes deterioration of myocardial function in the {delta}-sarcoglycan-deficient mouse model for dilated cardiomyopathy. Cardiovasc. Res., 2008, 79(4), 652-661.
70. Bauer, R.; Blain, A.; Greally, E.; Lochmuller, H.; Bushby, K.; MacGowan, G. A.; Straub, V. Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. Neuromuscul. Disord., 2010, 20(1), 21-28.
71. El-Helou, V.; Proulx, C.; Gosselin, H.; Clement, R.; Mimee, A.; Villeneuve, L.; Calderone, A. Dexamethasone treatment of post-MI rats attenuates sympathetic innervation of the infarct region. J. Appl. Physiol., 2008, 104(1), 150-156.
72. Mihailidou, A.S.; Loan Le, T.Y.; Mardini, M.; Funder, J.W. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension, 2009, 54(6), 1306-1312.
73. Hammerman, H.; Kloner, R.A.; Hale, S.; Schoen, F.J.; Braunwald, E. Dose-dependent effects of short-term methylprednisolone on myocardial infarct extent, scar formation, and ventricular function. Circulation, 1983, 68(2), 446-452.
74. Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol. Rev., 2004, 56(3), 387-437.
75. Ugurlucan, M.; Caglar, I.M.; Caglar, F.N.; Ziyade, S.; Karatepe, O.; Yildiz, Y.; Zencirci, E.; Ugurlucan, F.G.; Arslan, A.H.; Korkmaz, S.; Filizcan, U.; Cicek, S. Aspirin: from a historical perspective. Recent Pat. Cardiovasc. Drug Discov., 2012, 7 (1), 71-76.
76. Wu, R.; Laplante, M.A.; De Champlain, J. Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats. J. Hypertens, 2004, 22 (4), 793-801.
77. Wu, R.; Laplante, M.A.; de Champlain, J. Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. Hypertension, 2005, 45(6), 1139-1144.
78. Wang, X.; Lu, J.; Khaidakov, M.; Mitra, S.; Ding, Z.; Raina, S.; Goyal, T.; Mehta, J.L. Aspirin suppresses cardiac fibroblast proliferation and collagen formation through downregulation of angiotensin type 1 receptor transcription. Toxicol. Appl. Pharmacol., 2012, 259 (3), 346-354.
79. Wu, R.; Yin, D.; Sadekova, N.; Deschepper, C.F.; de Champlain, J.; Girouard, H. Protective effects of aspirin from cardiac hypertrophy and oxidative stress in cardiomyopathic hamsters. Oxid Med. Cell Longev., 2012, 2012, 761710.
80. Adamek, A.; Hu, K.; Bayer, B.; Wagner, H.; Ertl, G.; Bauersachs, J.; Frantz, S. High dose aspirin and left ventricular remodeling after myocardial infarction: aspirin and myocardial infarction. Basic Res. Cardiol., 2007, 102(4), 334-340.
81. Saito, T.; Rodger, I.W.; Hu, F.; Robinson, R.; Huynh, T.; Giaid, A. Inhibition of COX pathway in experimental myocardial infarction. J. Mol. Cell. Cardiol.,2004, 37(1), 71-77.
82. Shehadeh, A.A.; Arena, J.; Moschos, C.B.; Regan, T.J. Nonplatelet effects of aspirin during acute coronary occlusion: Electrophysiologic and cation alterations in ischemic myocardium. J. Cardiovasc. Pharmacol. Ther., 2000, 5(2), 113-1120.
83. Fu, Y.; Wang, Z.; Chen, W.L.; Moore, P.K.; Zhu, Y.Z. Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats. Am. J. Physiol. Heart Circ. Physiol., 2007, 293 (3), H1545-1552.
84. Burke, S.G.; Wainwright, C.L.; Vojnovic, I.; Warner, T.; Watson, D. G.; Furman, B. L. The effect of NCX4016 [2-acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester] on the consequences of ischemia and reperfusion in the streptozotocin diabetic rat. J. Pharmacol. Exp. Ther., 2006, 316(3), 1107-1114.
85. Farthing, D.; Gehr, L.; Karnes, H.T.; Sica, D.; Gehr, T.; Larus, T.; Farthing, C.; Xi, L. Effects of salicylic acid on post-ischaemic ventricular function and purine efflux in isolated mouse hearts. Biomarkers, 2007, 12(6), 623-634.
86. Birnbaum, Y.; Lin, Y.; Ye, Y.; Martinez, J.D.; Huang, M.H.; Lui, C.Y.; Perez-Polo, J.R.; Uretsky, B. F. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am. J. Physiol. Heart Circ. Physiol., 2007, 292(6), H2891-2897.
87. Jancso, G.; Cserepes, B.; Gasz, B.; Benko, L.; Ferencz, A.; Borsiczky, B.; Lantos, J.; Dureja, A.; Kiss, K.; Szeberenyi, J.; Roth, E. Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium. J. Cardiovasc. Pharmacol., 2005, 46 (3), 295-301.
88. Shinmura, K.; Kodani, E.; Xuan, Y.T.; Dawn, B.; Tang, X.L.; Bolli, R. Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. J. Am. Coll. Cardiol., 2003, 41 (7), 1183-1194.
89. Wang, B.H.; Bertucci, M.C.; Ma, J.Y.; Adrahtas, A.; Cheung, R.Y.; Krum, H. Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone. Clin. Exp. Pharmacol. Physiol., 2010, 37(9), 912-918.
90. Chu, L.M.; Robich, M.P.; Bianchi, C.; Feng, J.; Liu, Y.; Xu, S.H.; Burgess, T.; Sellke, F. W. Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia. Am. J. Physiol. Heart Circ. Physiol., 2012, 302(2), H479-488.
91. Robich, M.P.; Chu, L.M.; Feng, J.; Burgess, T.A.; Laham, R.J.; Bianchi, C.; Sellke, F. W. Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium. J. Thorac. Cardiovasc. Surg., 2010, 140 (5), 1143-1152.
92. Robich, M.P.; Chu, L.M.; Burgess, T.A.; Feng, J.; Bianchi, C.; Sellke, F.W. Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on myocardial function and perfusion. J. Cardiovasc. Pharmacol., 2011, 57(1), 122-130.
93. Lal, A.; Sharma, M.L. Failure to reduce experimental myocardial infarct size with ibuprofen pre-treatment in rats. Indian J. Physiol. Pharmacol., 1992, 36(2), 133-134.
94. Clement, R.; Das, D.K.; Engelman, R.M.; Otani, H.; Bandhyopadhyay, D.; Hoory, S.; Antar, M.; Rousou, J.A.; Breyer, R.H.; Prasad, M.R. Role of a nonsteroidal anti-inflammatory agent, ibuprofen, in coronary revascularization after acute myocardial infarction. Basic Res. Cardiol., 1990, 85(1), 55-70.
95. Jugdutt, B.I.; Idikio, H.; Uwiera, R.R. Therapeutic drugs during healing after myocardial infarction modify infarct collagens and ventricular distensibility at elevated pressures. Mol. Cell. Biochem., 2007, 304(1-2), 79-91.
96. Przyklenk, K. Effect of chronic ibuprofen therapy on early healing of experimentally induced acute myocardial infarction in dogs. Am. J. Cardiol.,1989, 63(15), 1146-1148.
97. Gross, E.R.; Hsu, A.K.; Gross, G.J. Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphineinduced cardioprotection: role of 12-lipoxygenase. J. Pharmacol. Exp. Ther., 2004, 310(1), 185-191.
98. Rossoni, G.; Manfredi, B.; Del Soldato, P.; Berti, F. The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion. J. Pharmacol. Exp. Ther., 2004, 310(2), 555-562.
99. Liao, X.; Wang, L.; Yang, C.; He, J.; Wang, X.; Guo, R.; Lan, A.; Dong, X.; Yang, Z.; Wang, H.; Feng, J.; Ma, H. Cyclooxygenase mediates cardioprotection of angiotensin-(1-7) against ischemia/reperfusion-induced injury through the inhibition of oxidative stress. Mol. Med. Report., 2011, 4(6), 1145-1150.
100. Wen, Q.; Sim, M.K.; Tang, F.R. Reduction of infarct size by orally administered des-aspartate-angiotensin I in the ischemic reperfused rat heart. Regul. Pept., 2004, 120(1-3), 149-153.
101. Gres, P.; Schulz, R.; Jansen, J.; Umschlag, C.; Heusch, G. Involvement of endogenous prostaglandins in ischemic preconditioning in pigs. Cardiovasc. Res., 2002, 55(3), 626-632.
102. Lozano, H.; Wu, D.; Bassuk, J.; Aria, J.; Kurlansky, P.; Lamas, G.A.; Adams, J.A. The effects of prostaglandin inhibition on whole-body ischemia-reperfusion in swine. Am. J. Emerg. Med., 2008, 26(1), 45-53.
103. Ibrahim, M.A.; Morsy, M.A.; Hafez, H.M.; Gomaa, W.M.; Abdelrahman, A.M. Effect of selective and non-selective cyclooxygenase inhibitors on doxorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicol. Mech. Methods., 2012, 22(6), 424-431.
104. Singh, B.K.; Pathan, R.A.; Pillai, K.K.; Haque, S.E.; Dubey, K. Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats. J. Cardiovasc. Pharmacol., 2010, 55 (2), 139-144.
105. Fan, X.; Takahashi-Yanaga, F.; Morimoto, S.; Zhan, D.Y.; Igawa, K.; Tomooka, K.; Sasaguri, T. Celecoxib and 2,5-dimethylcelecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model. J. Pharmacol. Exp. Ther., 2011, 338 (1), 2-11.
106. Jacobshagen, C.; Gruber, M.; Teucher, N.; Schmidt, A.G.; Unsold, B.W.; Toischer, K.; Nguyen, V.P.; Maier, L.S.; Kogler, H.; Hasenfuss, G. Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction. Eur. J. Heart Fail., 2008, 10(4), 334-342.
107. Streicher, J.M.; Kamei, K.; Ishikawa, T.O.; Herschman, H.; Wang, Y. Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. J. Mol. Cell. Cardiol., 2010, 49(1), 88-94.
108. Saito, T.; Rodger, I. W.; Shennib, H.; Hu, F.; Tayara, L.; Giaid, A. Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor. Can. J. Physiol. Pharmacol., 2003, 81(2), 114-119.
109. Straino, S.; Salloum, F.N.; Baldi, A.; Ockaili, R.A.; Piro, M.; Das, A.; Qureshi, I.Z.; Biasucci, L.M.; Capogrossi, M. C.; Biondi-Zoccai, G. G.; Severino, A.; Mellone, P.; Crea, F.; Vetrovec, G. W.; Kukreja, R.C.; Abbate, A. Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat. J. Cardiovasc. Pharmacol., 2007, 50(5), 571-577.
110. Salloum, F.N.; Hoke, N.N.; Seropian, I.M.; Varma, A.; Ownby, E. D.; Houser, J.E.; Van Tassell, B.W.; Abbate, A. Parecoxib inhibits apoptosis in acute myocardial infarction due to permanent coronary ligation but not due to ischemia-reperfusion. J. Cardiovasc. Pharmacol., 2009, 53(6), 495-498.
111. Abbate, A.; Limana, F.; Capogrossi, M. C.; Santini, D.; Biondi-Zoccai, G.G.; Scarpa, S.; Germani, A.; Straino, S.; Severino, A.; Vasaturo, F.; Campioni, M.; Liuzzo, G.; Crea, F.; Vetrovec, G.W.; Biasucci, L. M.; Baldi, A. Cyclo-oxygenase-2 (COX-2) inhibition reduces apoptosis in acute myocardial infarction. Apoptosis, 2006, 11(6), 1061-1063.
112. Scheuren, N.; Jacobs, M.; Ertl, G.; Schorb, W. Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction. J. Mol. Cell. Cardiol., 2002, 34(1), 29-37.
113. LaPointe, M.C.; Mendez, M.; Leung, A.; Tao, Z.; Yang, X. P. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am. J. Physiol. Heart Circ. Physiol., 2004, 286(4), H1416-424.
114. Abbate, A.; Salloum, F.N.; Ockaili, R.A.; Fowler, A.A., 3rd; Biondi-Zoccai, G.G.; Straino, S.; Lipinski, M.J.; Baldi, A.; Crea, F.; Biasucci, L.M.; Vetrovec, G.W.; Kukreja, R.C. Improvement of cardiac function with parecoxib, a cyclo-oxygenase-2 inhibitor, in a rat model of ischemic heart failure. J. Cardiovasc. Pharmacol., 2007, 49(6), 416-418.
115. Wu, D.; Mennerich, D.; Arndt, K.; Sugiyama, K.; Ozaki, N.; Schwarz, K.; Wei, J.; Wu, H.; Bishopric, N.H.; Doods, H. Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice. Prostag. Oth. Lipid M, 2009, 90(1-2), 21-25.
116. Timmers, L.; Sluijter, J.P.; Verlaan, C.W.; Steendijk, P.; Cramer, M. J.; Emons, M.; Strijder, C.; Grundeman, P.F.; Sze, S. K.; Hua, L.; Piek, J.J.; Borst, C.; Pasterkamp, G.; de Kleijn, D.P. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation, 2007, 115(3), 326-332.
117. Lada-Moldovan, L.; Kaloustian, S.; Bah, T.M.; Girard, S.A.; Dery, M.A.; Rousseau, G. Chronic pretreatment with celecoxib reduces infarct size. J. Cardiovasc. Pharmacol., 2009, 54(1), 31-37.
118. Carnieto, A., Jr.; Dourado, P.M.; Luz, P.L.; Chagas, A.C. Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia. Clinics (Sao Paulo), 2009, 64(3), 245-252.
119. Alcindor, D.; Krolikowski, J.G.; Pagel, P.S.; Warltier, D.C.; Kersten, J.R. Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology, 2004, 100(3), 547-554.
120. Sato, H.; Bolli, R.; Rokosh, G.D.; Bi, Q.; Dai, S.; Shirk, G.; Tang, X.L. The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats. Am. J. Physiol. Heart Circ. Physiol., 2007, 293(4), H2557-2564.
121. Guo, Y.; Bao, W.; Wu, W.J.; Shinmura, K.; Tang, X.L.; Bolli, R. Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res. Cardiol., 2000, 95(6), 479-484.
122. Shinmura, K.; Tang, X. L.; Wang, Y.; Xuan, Y.T.; Liu, S. Q.; Takano, H.; Bhatnagar, A.; Bolli, R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc. Natl. Acad. Sci. USA, 2000, 97(18), 10197-10202.
123. Tanaka, K.; Ludwig, L.M.; Krolikowski, J.G.; Alcindor, D.; Pratt, P. F.; Kersten, J.R.; Pagel, P.S.; Warltier, D.C. Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: Role of cyclooxygenase-2. Anesthesiology, 2004, 100(3), 525-531.
124. Tosaka, S.; Tosaka, R.; Matsumoto, S.; Maekawa, T.; Cho, S.; Sumikawa, K. Roles of cyclooxygenase 2 in sevoflurane-and olprinone-induced early phase of preconditioning and postconditioning against myocardial infarction in rat hearts. J. Cardiovasc. Pharmacol. Ther., 2011, 16(1), 72-78.
125. Feng, J.; Lucchinetti, E.; Fischer, G.; Zhu, M.; Zaugg, K.; Schaub, M.C.; Zaugg, M. Cardiac remodelling hinders activation of cyclooxygenase-2, diminishing protection by delayed pharmacological preconditioning: role of HIF1 alpha and CREB. Cardiovasc. Res., 2008, 78(1), 98-107.
126. Shinmura, K.; Nagai, M.; Tamaki, K.; Tani, M.; Bolli, R. COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts. Am. J. Physiol. Heart Circ. Physiol., 2002, 283(6), H2534-2543.
127. Kodani, E.; Xuan, Y.T.; Shinmura, K.; Takano, H.; Tang, X.L.; Bolli, R. Delta-opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits. Am. J. Physiol. Heart. Circ. Physiol., 2002, 283(5), H1943-1957.
128. Jiang, X.; Shi, E.; Nakajima, Y.; Sato, S.; Ohno, K.; Yue, H. Cyclooxygenase-1 mediates the final stage of morphine-induced delayed cardioprotection in concert with cyclooxygenase-2. J. Am. Coll. Cardiol., 2005, 45(10), 1707-1715.
129. Arnaud, C.; Joyeux-Faure, M.; Godin-Ribuot, D.; Ribuot, C. COX-2: an in vivo evidence of its participation in heat stress-induced myocardial preconditioning. Cardiovasc. Res., 2003, 58(3), 582-588.
130. Booth, E.A.; Flint, R.R.; Lucas, K. L.; Knittel, A.K.; Lucchesi, B. R. Estrogen protects the heart from ischemia-reperfusion injury via COX-2-derived PGI2. J. Cardiovasc. Pharmacol., 2008, 52 (3), 228-235.
131. Atar, S.; Ye, Y.; Lin, Y.; Freeberg, S. Y.; Nishi, S. P.; Rosanio, S.; Huang, M.H.; Uretsky, B.F.; Perez-Polo, J.R.; Birnbaum, Y. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am. J. Physiol. Heart Circ. Physiol., 2006, 290(5), H1960-1968.
132. Birnbaum, Y.; Ye, Y.; Rosanio, S.; Tavackoli, S.; Hu, Z.Y.; Schwarz, E.R.; Uretsky, B.F. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemiareperfusion injury. Cardiovasc. Res., 2005, 65(2), 345-355.
133. Dowd, N.P.; Scully, M.; Adderley, S.R.; Cunningham, A.J.; Fitzgerald, D.J. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J. Clin. Invest., 2001, 108(4), 585-590.
134. Delgado, R.M.; Nawar, M.A.; Zewail, A.M.; Kar, B.; Vaughn, W. K.; Wu, K.K.; Aleksic, N.; Sivasubramanian, N.; McKay, K.; Mann, D.L.; Willerson, J.T. Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation, 2004, 109(11), 1428-1433.
135. Isic, A.; Scharin Tang, M.; Haugen, E.; Fu, M. TNFalphaantagonist neither improve cardiac remodelling or cardiac function at early stage of heart failure in diabetic rats. Autoimmunity, 2008, 41(6), 473-477.
136. Kubota, T.; Bounoutas, G.S.; Miyagishima, M.; Kadokami, T.; Sanders, V.J.; Bruton, C.; Robbins, P.D.; McTiernan, C.F.; Feldman, A. M. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation, 2000, 101(21), 2518-2525.
137. Cirino, G.; Distrutti, E.; Wallace, J. L. Nitric oxide and inflammation. Inflamm. Allergy. Drug Targets, 2006, 5(2), 115-119.
138. Borhade, N.; Pathan, A.R.; Halder, S.; Karwa, M.; Dhiman, M.; Pamidiboina, V.; Gund, M.; Deshattiwar, J.J.; Mali, S.V.; Deshmukh, N.J.; Senthilkumar, S. P.; Gaikwad, P.; Tipparam, S. G.; Mudgal, J.; Dutta, M. C.; Burhan, A. U.; Thakre, G.; Sharma, A.; Deshpande, S.; Desai, D. C.; Dubash, N.P.; Jain, A.K.; Sharma, S.; Nemmani, K.V.; Satyam, A. NO-NSAIDs. Part 3: Nitric oxidereleasing prodrugs of non-steroidal anti-inflammatory drugs. Chem. Pharm. Bull (Tokyo), 2012, 60(4), 465-481.
139. Nixon, M.; Upreti, R.; Andrew, R. 5alpha-Reduced glucocorticoids: A story of natural selection. J. Endocrinol., 2012, 212(2), 111-127.
140. Yang, C.; Nixon, M.; Kenyon, C.J.; Livingstone, D.E.; Duffin, R.; Rossi, A.G.; Walker, B.R.; Andrew, R. 5alpha-reduced glucocorticoids exhibit dissociated anti-inflammatory and metabolic effects. Br. J. Pharmacol., 2011, 164(6), 1661-1671.